Sara M Camp1, Alexander Marciniak2, Eddie T Chiang1, Alexander N Garcia3, Robert Bittman4, Robin Polt2, Ruth G Perez5, Steven M Dudek6, Joe G N Garcia1. 1. Department of Medicine, The University of Arizona, Tucson, AZ, USA. 2. Department of Chemistry and Biochemistry, The University of Arizona, Tucson, AZ, USA. 3. Department of Radiation Oncology, The University of Arizona, Tucson, AZ, USA. 4. Department of Chemistry and Biochemistry, Queens College of the City University of New York, Flushing, NY, USA. 5. Department of Molecular and Translational Medicine, Graduate School of Biomedical Sciences, Center of Emphasis in Neuroscience, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA. 6. Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA.
Abstract
RATIONALE: Vascular permeability is a hallmark of acute respiratory distress syndrome (ARDS) and ventilator-induced lung injury pathobiology; however, the mechanisms underlying this vascular dysregulation remain unclear, thereby impairing the development of desperately needed effective therapeutics. We have shown that sphingosine-1-phosphate (S1P) and 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol (FTY720) analogues are useful tools for exploring vascular barrier regulation mechanisms. OBJECTIVE: To experimentally define the effects of FTY720 regioisomers on lung endothelial cell barrier regulation. METHODS: Specific barrier-regulatory receptor and kinase inhibitors were utilized to probe signaling mechanisms involved in FTY720 regioisomer-mediated human lung endothelial cell barrier responses (trans-endothelial electrical resistance, TER). Docking simulations with the S1P1 receptor were performed to further evaluate FTY720 regioisomer signaling. RESULTS: FTY720 regioisomers produced potent endothelial cell barrier disruption reflected by declines in TER alterations. Pharmacologic inhibition of Gi-coupled S1P receptors (S1P1, S1P2, S1P3) failed to alter FTY720 regioisomer-mediated barrier disruption; findings that were corroborated by docking simulations demonstrating FTY720 regiosomers were repelled from S1P1 docking, in contrast to strong S1P1 binding elicited by S1P. Inhibition of either the barrier-disrupting PAR-1 receptor, the VEGF receptor, Rho-kinase, MAPK, NFkB, or PI3K failed to alter FTY720 regioisomer-induced endothelial cell barrier disruption. While FTY720 regioisomers significantly increased protein phosphatase 2 (PP2A) activity, PP2A inhibitors failed to alter FTY720 regioisomer-induced endothelial cell barrier disruption. CONCLUSIONS: Together, these results imply a vexing model of pulmonary vascular barrier dysregulation in response to FTY720-related compounds and highlight the need for further insights into mechanisms of vascular integrity required to promote the development of novel therapeutic tools to prevent or reverse the pulmonary vascular leak central to ARDS outcomes.
RATIONALE: Vascular permeability is a hallmark of acute respiratory distress syndrome (ARDS) and ventilator-induced lung injury pathobiology; however, the mechanisms underlying this vascular dysregulation remain unclear, thereby impairing the development of desperately needed effective therapeutics. We have shown that sphingosine-1-phosphate (S1P) and 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol (FTY720) analogues are useful tools for exploring vascular barrier regulation mechanisms. OBJECTIVE: To experimentally define the effects of FTY720 regioisomers on lung endothelial cell barrier regulation. METHODS: Specific barrier-regulatory receptor and kinase inhibitors were utilized to probe signaling mechanisms involved in FTY720 regioisomer-mediated human lung endothelial cell barrier responses (trans-endothelial electrical resistance, TER). Docking simulations with the S1P1 receptor were performed to further evaluate FTY720 regioisomer signaling. RESULTS: FTY720 regioisomers produced potent endothelial cell barrier disruption reflected by declines in TER alterations. Pharmacologic inhibition of Gi-coupled S1P receptors (S1P1, S1P2, S1P3) failed to alter FTY720 regioisomer-mediated barrier disruption; findings that were corroborated by docking simulations demonstrating FTY720 regiosomers were repelled from S1P1 docking, in contrast to strong S1P1 binding elicited by S1P. Inhibition of either the barrier-disrupting PAR-1 receptor, the VEGF receptor, Rho-kinase, MAPK, NFkB, or PI3K failed to alter FTY720 regioisomer-induced endothelial cell barrier disruption. While FTY720 regioisomers significantly increased protein phosphatase 2 (PP2A) activity, PP2A inhibitors failed to alter FTY720 regioisomer-induced endothelial cell barrier disruption. CONCLUSIONS: Together, these results imply a vexing model of pulmonary vascular barrier dysregulation in response to FTY720-related compounds and highlight the need for further insights into mechanisms of vascular integrity required to promote the development of novel therapeutic tools to prevent or reverse the pulmonary vascular leak central to ARDS outcomes.
Authors: Jeffrey J Hale; William Neway; Sander G Mills; Richard Hajdu; Carol Ann Keohane; Mark Rosenbach; James Milligan; Gan-Ju Shei; Gary Chrebet; James Bergstrom; Deborah Card; Gloria C Koo; Sam L Koprak; Jesse J Jackson; Hugh Rosen; Suzanne Mandala Journal: Bioorg Med Chem Lett Date: 2004-06-21 Impact factor: 2.823
Authors: Michael A Hanson; Christopher B Roth; Euijung Jo; Mark T Griffith; Fiona L Scott; Greg Reinhart; Hans Desale; Bryan Clemons; Stuart M Cahalan; Stephan C Schuerer; M Germana Sanna; Gye Won Han; Peter Kuhn; Hugh Rosen; Raymond C Stevens Journal: Science Date: 2012-02-17 Impact factor: 47.728
Authors: S M Camp; R Bittman; E T Chiang; L Moreno-Vinasco; T Mirzapoiazova; S Sammani; X Lu; C Sun; M Harbeck; M Roe; V Natarajan; J G N Garcia; S M Dudek Journal: J Pharmacol Exp Ther Date: 2009-07-10 Impact factor: 4.030
Authors: Javier Vargas-Medrano; Sesha Krishnamachari; Ernesto Villanueva; Wesley H Godfrey; Haiyan Lou; Ramesh Chinnasamy; Jeffrey B Arterburn; Ruth G Perez Journal: ACS Med Chem Lett Date: 2014-05-27 Impact factor: 4.345
Authors: Patrick Grailhe; Asma Boutarfa-Madec; Philippe Beauverger; Philip Janiak; Ashfaq A Parkar Journal: FEBS Open Bio Date: 2020-09-04 Impact factor: 2.792